Publications

Venous Thromboprophylaxis in Surgical Oncology Patients: The Importance of Risk Assessment in the Context of Limited Evidence

Snyder RA, O'Reilly EM

When Radiotherapy and Immunotherapy Dance—Who Leads So as Not to Step on Toes?

F Balogun, D Raben

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, et al.

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

W Park, EM O'Reilly, J Furuse, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer

D Arnold, T Golan, P Hammel, M Reni, E Van Cutsem, TM Mercade, ...

1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

T Golan, P Hammel, M Reni, E Van Cutsem, TM Mercade, MJ Hall, ...

343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic …

D Maurer, JX Yu, K Sklodowski, M Tognetti, L Reiter, R Bruderer, ...

A Review of Pancreatic Cancer-Reply

Park W, Chawla A, O'Reilly EM

Abstract No. 86 Treatment of pancreatic cancer by intra-arterial injection of an emulsion of lipiodol and bumetanide (an anti-glycolytic drug) in a transgenic mutated pig model …

H Yarmohammadi, A Elsakka, F Nurili, A Maxwell, F Ridouani, E Ziv, ...

Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

MHG Katz, Q Shi, JP Meyers, JM Herman, M Choung, BM Wolpin, ...

Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO)+ sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

IH El Dika, SM Geyer, AB Nixon, F Innocenti, Q Shi, SB Jacobson, ...

Assessment of ADI-PEG 20 and modified FOLFOX6 in advanced hepatocellular carcinoma patients: Results of an international, single-arm, phase 2 study

JJ Harding, TS Yang, YY Chen, YH Feng, CJ Yen, CL Ho, WT Huang, ...

Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study

Harding JJ, Yang TS, Chen YY, Feng YH, Yen CJ, Ho CL, Huang WT, El Dika I, et al.

Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer

Reyngold M, O'Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, … Park W, …

Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide

Sishc BJ, Ding L, Nam TK, Heer CD, Rodman SN, Schoenfeld JD, Fath MA, Saha D, et al.

Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or …

JE Till, A Abdalla, N Bhagwat, TA Black, Z Wang, SS Yee, PF Gherardini, ...

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label …

MH O'Hara, EM O'Reilly, G Varadhachary, RA Wolff, ZA Wainberg, AH Ko, ...

Clarity Plus Confidence: Leveraging eConsent to Assess Participant Agency in the Consent Process

MR O'Shea, M Buckley, J Wang, J Galle, M Lin, M Koch, J Lengfellner, ...

Clinical trials of systemic chemotherapy for resectable pancreatic cancer: a review

MN Mavros, D Moris, PJ Karanicolas, MHG Katz, EM O’Reilly, TM Pawlik

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 …

R Cohen, Q Shi, J Meyers, Z Jin, M Svrcek, C Fuchs, F Couture, P Kuebler, ...

Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with …

MR Weiser, JF Chou, A Keshinro, WC Chapman Jr, PS Bauer, MG Mutch, ...

Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).

E Van Blarigan, C Ma, FS Ou, AP Venook, K Ng, D Niedzwiecki, ...

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.

SM Geyer, MR Mahoney, TR Asmis, N Hall, S Karovic, MV Knopp, ...

Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes

Varghese AM, Singh I, Singh R, Kunte S, Chou JF, Capanu M, Wong W, … Park W, …

Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB/SWOG 80702 (Alliance …

JA Meyerhardt, Q Shi, CS Fuchs, J Meyer, D Niedzwiecki, T Zemla, ...

Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions

AM Schram, E O’Reilly, G O’Kane

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, Meng F, Haque M, et al.

Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC).

GK Abou-Alfa, T Meyer, J Zhang, S Sherrin, A Yaqubie, A Clemens O’Neill, ...

Gemcitabine (Gem) and nab-paclitaxel (NP)±nivolumab (nivo)±CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic …

MH O'Hara, EM O'Reilly, RA Wolff, ZA Wainberg, AH Ko, OE Rahma, ...

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, … Park W, …

IGF-binding proteins, adiponectin, and survival in metastatic colorectal cancer: results from CALGB (Alliance)/SWOG 80405

BJ Guercio, S Zhang, FS Ou, AP Venook, D Niedzwiecki, HJ Lenz, ...

Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective

B Zheng-Lin, EM O’Reilly

Immunotherapy in Advanced Biliary Tract Cancers

Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D

Improving outcomes and shared decisions in pancreatic cancer using animated pancreas patient (APP) visual formats of learning: A National Pancreas Foundation (NPF) patient …

S Munigala, EM O'Reilly, M Alsante, J Holt, AH Ko, A Gelrud

Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.

K DiNardo, C Ma, FS Ou, C Yuan, BJ Guercio, V Morales-Oyarvide, ...

LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P+ Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year …

M Tempero, E O'Reilly, E Van Cutsem, J Berlin, P Philip, D Goldstein, ...

Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity

O'Connor CA, Park JS, Kaley T, Kezlarian B, Edelweiss M, Yang TJ, Park W, Reidy D, et al.

Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement

Jolissaint JS, Reyngold M, Bassmann J, Seier KP, Gönen M, Varghese AM, Yu KH, Park W, et al.

MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

DY Oh, JO Park, HL Kindler, P Hammel, M Reni, E Van Cutsem, ...

Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?

TL Sutton, A Grossberg, F Ey, EM O’Reilly, BC Sheppard

MULTIOMIC BIOMARKER SIGNATURES IDENTIFY SUBSETS OF PATIENTS WHO MAY BENEFIT FROM EITHER NIVOLUMAB OR SOTIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC PANCREATIC CANCER

D Maurer, JX Yu, K Sklodowski, M Tognetti, L Reiter, R Bruderer, ...

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study …

PM Morice, A Leary, C Dolladille, B Chrétien, L Poulain, ...

Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations

AM Varghese, J Patel, YY Janjigian, F Meng, SD Selcuklu, G Iyer, ...

Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States

May MS, Kinslow CJ, Adams C, Saqi A, Shu CA, Chaudhary KR, Wang TJC, Cheng SK

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ...

P86. 08 phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors

A Schram, T Macarulla, E O’Reilly, J Rodon, B Wolpin, S Ou, D Kim, ...

Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes

Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, et al.

Pancreas cancer: Therapeutic trials in metastatic disease

Smithy JW, O'Reilly EM

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma

Askan G, Sahin IH, Chou JF, Yavas A, Capanu M, Iacobuzio-Donahue CA, Basturk O, O'Reilly EM

Pancreatic cancer: a review

Park W, Chawla A, O'Reilly EM